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The inability of papillomaviruses (PV) to replicate in tissue culture cells has hampered the study of the PV
life cycle. We investigated virus-cell interactions by the following two methods: (i) using purified bovine PV
virions or human PV type 11 (HPV type 11) virus-like particles (VLP) to test the binding to eukaryotic cells and
(ii) using different VLP-reporter plasmid complexes of HPV6b, HPV11 L1 or HPV11 L1/L2, and HPV16 L1 or
HPV16 L1/L2 to study uptake of particles into different cell lines. Our studies showed that PV capsids bind to
a broad range of cells in culture in a dose-dependent manner. Binding of PV capsids to cells can be blocked
by pretreating the cells with the protease trypsin. Penetration of PV into cells was monitored by using
complexes in which the purified PV capsids were physically linked to DNA containing the gene for b-galac-
tosidase driven by the human cytomegalovirus promoter. Expression of b-galactosidase occurred in <1% of the
cells, and the efficiency of PV receptor-mediated gene delivery was greatly enhanced (up to 10 to 20% positive
cells) by the use of a replication-defective adenovirus which promotes endosomal lysis. The data generated by
this approach further confirmed the results obtained from the binding assays, showing that PV enter a wide
range of cells and that these cells have all functions required for the uptake of PV. Binding and uptake of PV
particles can be blocked by PV-specific antisera, and different PV particles compete for particle uptake. Our
results suggest that the PV receptor is a conserved cell surface molecule(s) used by different PV and that the
tropism of infection by different PV is controlled by events downstream of the initial binding and uptake.
Papillomaviruses (PVs) are epitheliotropic double-stranded
DNA viruses which induce benign proliferation of the epithe-
lium and, in some instances, of fibroblasts. Infection of human
cervical epithelial cells with certain human PVs (HPV), e.g.,
HPV types 16 or 18 (HPV16 or HPV18), is associated with the
development of lesions which can progress to cervical cancer
(39). The PV genome apparently utilizes the host cell machin-
ery to replicate episomally in dividing stem cells (11), while
infectious virions are assembled in differentiated epithelial
cells (9). However, studying the PV life cycle has proved dif-
ficult, because the PV vegetative life cycle is linked to terminal
differentiation of keratinocytes, and it has not yet proved pos-
sible to replicate the entire life cycle in cell culture (31).
To initiate infection, PVs are presumed, like other viruses,
to attach to cells through interaction between the viral capsid
and cell membrane components, i.e., the PV receptor. Since
the PV capsids are composed of multiple identical units (the
structural proteins L1 and L2), the virion very likely possesses
the capacity to bind to its receptor through multivalent inter-
actions. This could provide them with high-affinity binding
properties either via few high-affinity interactions or multiple
low-affinity interactions, as has been shown for adenovirus type
2 (36).
Very little is known about the nature of the PV receptor and
mechanisms involved in virus entry into host cells. Bovine PV
type 1 (BPV1) virions can enter a number of different types of
cells, including epithelial cells and fibroblasts (for review, see
reference 20). The range of cells which can be transformed in
vitro by BPV1 is broader in terms of both species and tissue
specificity than the range of cells that are permissive in vivo for
vegetative replication, suggesting that the observed restriction
of PV vegetative replication to epithelial cells is determined by
cellular regulation of the viral transcription program by cellu-
lar factors, rather than by restriction of the PV receptor to a
limited host cell range.
The PV L1 protein has the capacity to self-assemble into
virus-like particles (VLPs) within intact cells in culture (15, 17,
27, 37, 38), and these can be purified for in vitro studies.
Taking advantage of the availability of large quantities of PV
capsids, we examined the details of the reaction of PV binding
onto the surfaces of different cell lines by using purified PV
capsids. The binding of viral particles to cells does not neces-
sarily mean that the particles can be taken up by the cells, since
many viruses need to interact with more than one cellular
molecule for high-affinity binding and penetration (12, 28, 30,
36). Therefore, we tested if the PVs that are bound to a re-
ceptor can penetrate the cells by receptor-mediated endocyto-
sis using a VLP-reporter plasmid complex in which the PV
capsid was physically linked to a plasmid containing the Esch-
erichia coli lacZ gene. Delivery of the reporter gene into the
cells by the PV capsids could then be examined by in situ
b-galactosidase (b-Gal) staining. Our results show that PVs
can bind to and be internalized by a large range of cell lines in
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vitro and that different PVs seem to use the same receptor to
enter their host cells.
MATERIALS AND METHODS
Cells and cell culture. The cell lines that were tested were obtained from the
American Type Culture Collection and were grown in Dulbecco’s modified
Eagle’s medium (BRL) with 10% fetal calf serum (FCS) (Sigma) at a density of
105 cells per ml at 378C and with 5% CO2. Spodoptera frugiperda Sf9 cells were
cultivated using TNM-FH insect medium (Sigma) with 10% FCS at 278C. K20
cells were derived from the human lymphoma B-cell line BJAB (16).
Construction of recombinant plasmids. Plasmid pVL11L1 (HPV11 L1) was
constructed by PCR amplification of the L1 gene from a BamHI-digested and
religated HPV11 genomic clone using the following primers: 59-AAA GAA TTC
GAC GCC GTA AAC GTA TTC CC-39 and 59-AAA AGA TCT ACA ACA
ACA TAT AAA T-39. The amplified fragment was then ligated into the EcoRI
and BglII sites of the transfer vector pVL1393 (Invitrogen). The plasmid
pVL11L2 (HPV11 L2) was cloned using the primers 59-AAA GAA TTC TTT
ATA CAG TGT GTG GTG TA-39 and 59-AAA GGA TCC ACA GGG TTG
GGA GGA GGC AC-39 and was ligated into EcoRI and BglII of pVL1393. The
HPV6b L1 open reading frame was cloned using primers 59-CG CCC GGG TTA
CCT TTT AGT TTG GCG CGC TTA CGT TTA GG-39 and 59-GC GGA TCC
AGA TGT GGC GGC CTA GCG ACA GCA CAG TAT ATG-39.
Production of baculovirus recombinants. S. frugiperda Sf9 cells were grown as
suspension or monolayer cultures in TNM-FH insect medium (Sigma) with 10%
FCS–2 mM glutamine at 278C. For HPV6b and HPV11 recombinant baculovirus
construction, 5 mg of plasmid was used to transfect Sf9 cells together with 5 mg
of linearized Baculo-Gold DNA (Pharmingen, San Diego, Calif.). Recombinant
viruses were purified by standard methods as suggested by the manufacturer. The
HPV16 L1- and L1/L2-expressing baculovirus recombinants were gifts from R.
Kirnbauer (18). For expression of PV capsid proteins, 106 Sf9 cells were infected
with baculovirus recombinants at a multiplicity of infection of 5 to 10. After
incubation, medium was removed, and the cells were washed with phosphate-
buffered saline (PBS). The cells were then lysed in sodium dodecyl sulfate (SDS)
sample buffer for SDS-polyacrylamide gel electrophoresis and immune blotting
assays.
PV capsid purification. All VLPs were generated from baculovirus recombi-
nants. For VLP purification, 500 ml of Sf9 cells (1 3 106 to 3 3 106 cells per ml)
was infected with L1 (L1/L2) recombinant baculovirus. After incubation for 3
days, the cells were harvested and lysed in 10 ml of extraction buffer (1 mM
HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid; pH 7.], 150 mM
NaCl, 50 mM CaCl2, 10 mM MgCl2) containing 2 mM phenylmethylsulfonyl
fluoride. The lysate was then cleared by centrifugation at 10,000 3 g for 10 min
and enriched for particles by centrifugation through a 40% sucrose cushion (5
mM HEPES [pH 7.5], 10 mM CaCl2, 10 mM MgCl2) at 100,000 3 g for 2 h. The
pellet was resuspended in extraction buffer containing 31% CsCl and further
purified by equilibrium centrifugation. VLPs were collected and examined by
electron microscopy (Fig. 1). For the purification of BPV complete particles,
cattle warts were minced and then extracted essentially in the way described for
the PV VLPs.
Electron microscopy. Fractions of CsCl density gradients containing PV L1
proteins, which were demonstrated by immunoblots with appropriate antibodies,
were dialyzed against 5 mMHEPES buffer (pH 7.4). Virus particles were stained
with 2% aqueous uranyl acetate and examined in a Zeiss EM 10 electron
microscope.
Binding assays. (i) Indirect binding assay. BPV particles (about 1.5 3 104 to
1.25 3 105 particles in 100 ml) of CsCl-purified BPV virions were mixed with
suspensions of cells (2 3 105 to 1 3 106 cells per well) for 45 min at 378C in a
96-well microtiter plate previously blocked with gelatin, in a total volume of 200
ml. Cells grown as monolayer were lifted from the culture flasks by EDTA
treatment. Particles absorbed to cells were removed by low-speed centrifugation.
Cell free-supernatant (100 ml) was collected and used in an antigen capture
enzyme-linked immunosorbent assay (ELISA) to quantify the remaining BPV
particles. For the ELISA, 96-well microtiter plates were coated with a 1:500
dilution of anti-BPV1 antibody AU2 (5) overnight in 0.1 M sodium carbonate
buffer (pH 9.6). The plates were washed and blocked with 5% bovine serum
albumin (BSA) in PBS. The plates were then incubated with different dilutions
of BPV particles. After extensive washing, the plates were then incubated with a
rabbit anti-BPV1 antiserum and then with anti-rabbit peroxidase-conjugated
immunoglobulin G (Southern Biotechnology) at a 1:5,000 dilution. The plates
were stained by adding 100 ml of ABTS [2,29-azino-bis(3-ethylbenz-thiazoline-6-
sulfonic acid)] staining solution (1 mg/ml in a 100 mM sodium acetate-phosphate
buffer [pH 4.2] containing 0.015% H2O2). After color development, the A405 was
measured in an automated ELISA reader. To examine whether trypsin pretreat-
ment of cells could alter PV particle binding, cells were exposed to 0.1% trypsin
for 5 min, and trypsin activity was neutralized by the addition of medium con-
taining 10% FCS and then by repetitive washing of the cells with PBS. Binding
results are expressed as a percentage of virions bound to each cell type. To
establish BPV binding to each cell type, suspensions of BPV particles to which
the cell type being tested or an equal volume of saline had been added were
assayed for BPV protein after the cell with adsorbed virus had been removed by
centrifugation. The background of the antigen capture ELISA was measured on
antibody-coated wells without the addition of any BPV antigen and was subse-
quently subtracted from values of all other wells. The percentage of BPV binding
to cells was then calculated as 1003 (OD with saline 2 OD with cells)/OD with
saline added, where OD is optical density.
(ii) Direct binding assay. Cells grown in 96-well plates were fixed with ice-cold
methanol-acetone (1:1). The plates were then washed six times with PBS–0.05%
Tween 20 and incubated with HPV11 VLPs (about 0.1 mg/ml in 3% BSA–PBS–
0.05% Tween 20) for 1 h at 378C. The cells were then washed four times with
PBS–0.05% Tween 20 and subsequently incubated with a monoclonal antibody
(MAb), A3 (1:5,000), against HPV11 L1 (2). After washing, a goat horseradish
peroxidase-conjugated anti-mouse immunoglobulin G (Southern Biotechnology)
was added (1:3,000), and the amount of immunoglobulin G retained in wells was
measured as described above.
Preparation of VLP-reporter plasmid complexes. The reporter plasmid
(pNeob) was constructed as follows. The b-galactosidase (b-Gal) gene was
isolated by NotI digestion from plasmid pSVb (Clonetech) and was cloned into
the NotI site downstream from the cytomegalovirus promoter of pCNDA3 (In-
vitrogen), which in addition contains a G418 resistance gene. The resulting
plasmid (pNeob [8.9 kb]) was purified twice by CsCl gradient centrifugation.
Purified VLPs were coupled to polylysine according to previously described
methods (8, 9). Briefly, 100 mg of PV capsids purified by CsCl gradient centrif-
ugation was dialyzed against HBS buffer (150 mM NaCl, 20 mM HEPES [pH
7.3]) to remove CsCl. The PV capsids were then mixed with polylysine (molec-
ular mass, 23.7 kDa; Sigma) with a final concentration of 150 mM in the presence
of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) at 2 mM in 4 ml of
HBS buffer. After incubation at 48C overnight, the capsids were purified by CsCl
gradient centrifugation to remove unreacted chemicals. The modified VLPs were
then dialyzed against HBS before the addition of 10 mg of plasmid DNA to
approximately 25 mg of VLPs.
VLP-reporter plasmid complexes were made in 500 ml of HBS. Ten micro-
grams of pNeob plasmid in 250 ml of HBS was mixed with 250 ml of modified PV
capsids (25 mg). After incubation at room temperature for 30 min, the complex
was added to cells for uptake analysis.
FIG. 1. Electron micrograph of HPV11 L1 VLP purified from recombinant
baculovirus-infected cells. The bars in the upper and lower parts indicate lengths
of 200 and 100 nm, respectively.
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Purification of adenovirus particles. The replication-defective adenovirus type
5 (strain dl312) was grown in 293 cells (6, 7). The cells that were infected with
dl312 virus were frozen and thawed three times, and the crude virus extracts were
purified by spinning in a Beckman SW28 rotor at 26,000 rpm for 2 h and then by
CsCl gradient centrifugation. The titer of purified dl312 viruses was determined
as previously described (6).
Analysis of the uptake of VLP-reporter plasmid complexes in tissue culture
cells. The cells were plated at 105 per well into 24-well tissue culture plates and
were grown in 0.25 ml of Dulbecco’s modified Eagle’s medium medium with 10%
FCS. Before the addition of the VLP-reporter plasmid complexes, the cells were
washed twice with fresh medium without FCS, and the VLP-reporter plasmid
complex was mixed with medium containing 10% FCS and added to the cells for
4 h at 378C. At the end of this period, the medium was removed and replaced by
prewarmed fresh medium with 10% FCS, and the cells continued to be incubated
at 378C for 36 h. The cells were then washed with PBS and stained for b-Gal
expression.
b-Gal staining. The cells that were infected by VLP-reporter plasmid com-
plexes containing the b-Gal gene were fixed with 2% formaldehyde in PBS for 5
min. The cells were incubated with X-Gal (5-bromo-4-chloro-3-indolyl-b-D-ga-
lactopyranoside) staining buffer [2 mM MgCl2, 3 mM K3Fe(CN)6, 3 mM
K4Fe(CN6), 1 mg of X-Gal (Sigma) per ml in PBS] at room temperature for up
to 1 h. Then, the cells were washed with 5% dimethyl sulfoxide in PBS and
visualized using a light microscope. The number of blue cells per 1,000 cells was
determined for each experiment.
RESULTS
Binding of PV particles to cells of different lines. We used
two assay systems to measure binding of PV particles to cul-
tured cell lines. First, cells were suspended in a preparation of
BPV particles that were purified from cattle warts. The abili-
ties of different cell types to adsorb BPV particles were assayed
by measuring the BPV particles remaining in suspension by an
antigen-capture ELISA after the cells had been removed by
low-speed centrifugation. All cell lines tested (K20, C127, Sf9,
and HeLa) adsorbed PV particles (Fig. 2A). The best adsorp-
tion was seen with C127 cells; more than 90% of immunore-
active BPV antigen was removed from the supernatant by
these cells. The fraction of BPV particles bound by each cell
type was inversely proportional to the concentration of parti-
FIG. 2. Binding of PV capsids to different cell lines. (A) Adsorption of BPV virions to various cell lines. Results are expressed as percentages of virions bound to
each cell type. To establish BPV binding, suspensions of BPV particles to which the cells being tested or an equal volume of saline had been added were assayed for
BPV protein after the cells with absorbed virus had been removed by centrifugation. Percentages of BPV binding to cells were then calculated as described in Materials
and Methods. Results for K20 cells (human lymphoma B-cell line), C127 cells (mouse mammary tumor cells), and HeLa cells (human cervical carcinoma cells), either
untreated or exposed to trypsin prior to assaying, are given. (B) Dose-dependent binding of BPV particles to C127 cells. Decreasing amounts of BPV particles were
incubated with a constant number of cells in the assay described for panel A. At a low concentration of BPV (1:6,400 dilution) containing approximately 1.25 3 105
particles, more than 90% of the BPV antigen was immobilized by 8 3 104 C127 cells. (C) Binding of HPV11 L1-formed VLPs to cell monolayers assessed by ELISA.
Cells were fixed in 96-well plates, and VLPs were added. Results show binding of the VLPs to a range of cell lines assessed by ELISA for L1 protein. Results are
expressed as the L1 protein ELISA (E) optical density readings obtained with cells exposed to VLP minus the ELISA optical densities of the same cells that were not
exposed. For each cell type (see also Table 1), inhibition of binding by prior exposure of the particles to an HPV6b L1-specific polyclonal rabbit antiserum is also shown.
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cles and reached almost 100% at high dilutions (about 1.25 3
105 particles per 8 3 104 [Fig. 2B]). Binding of BPV particles
to cells could in each case be reduced by pretreatment of the
cells with trypsin (Fig. 2A). Since even insect Sf9 cells were
able to bind more than 75% of the BPV preparation, other
assays were developed to confirm that the observed binding
was specific. To further investigate the interaction between PV
particles and cells, a direct ELISA was developed in which
monolayers of fixed adherent cells were exposed to PV VLPs
prepared from Sf9 cells infected with HPV11 L1 recombinant
baculovirus (Fig. 1). Binding of VLPs was assessed with a MAb
specific for HPV11 L1 capsids (2). Each of 11 tested cell lines
was able to bind VLPs, and in each case this binding could in
part be prevented by prior exposure of the particles to a rabbit
polyclonal antiserum raised against HPV6b L1 which was
cross-reactive with HPV11 L1 (Fig. 2C).
Internalization of PV particles into cultured cells. Many
viruses are able to bind nonspecifically to cells, which usually
does not result in virus uptake and infection of a cell (32). To
measure uptake and internalization of PV particles (BPV or
baculovirus-derived HPV6b, HPV11, and HPV16 VLPs com-
posed of L1 alone or of the L1 and L2 proteins), VLPs were
physically linked to a b-Gal reporter plasmid whose expression
was used as a measure of particle uptake (4). When VLP-
reporter plasmid complexes were applied to HeLa cells, b-Gal
expression was detected after 48 h. However, enzyme activity
was detected only in less than 1% of all exposed cells (Fig. 3B).
No cells expressed b-Gal when a mixture of unlinked PV and
reporter plasmid DNA was used (Fig. 3A). To investigate
whether failure of release of the intact reporter construct from
lysosomes was the reason why only a small proportion of cells
exhibited b-Gal activity, we infected cells with a replication-
defective adenovirus which facilitates lysis of lysosome mem-
branes (24) (Fig. 4) at the time of addition of VLP-reporter
plasmid complexes. Cells infected with adenovirus and simul-
taneously exposed to VLP-reporter plasmid constructs ex-
pressed b-Gal 10 to 20 times more frequently than cells not
infected with adenovirus, resulting in about 10 to 20% positive
cells (Fig. 3D). VLP-reporter plasmid constructs composed of
HPV16 L1 and L2 proteins delivered the DNA into cells as
efficiently as the VLP-reporter plasmid complex made of L1
alone, suggesting that the L2 protein is not necessary for PV
binding and penetration. No positive cells were found when a
mixture of unmodified PV capsids and reporter plasmid con-
struct was added to cells along with dl312 adenovirus (Fig. 3C).
Inhibition of VLP-reporter plasmid complex uptake by PV-
specific antisera. PV capsid-reporter plasmid complexes were
mixed with a rabbit antiserum raised against HPV6b L1 and
were then added to confluent monolayers of HeLa cells to-
gether with adenovirus strain dl312. After 48 h of incubation,
the cells were stained for b-Gal activity. Reduction of b-Gal-
positive cells was observed in a PV genotype-specific fashion
(Fig. 5A). The antiserum was able to reduce uptake and ex-
pression of b-Gal linked to HPV6b L1 VLPs or HPV11 L1
VLPs but did not block uptake of HPV16 L1 VLPs or BPV
particles. A MAb (H3) that was reported to be neutralizing for
HPV11 (2) also blocked the uptake of HPV6b L1 and HPV11
L1 VLP-reporter gene complexes (Fig. 5A), while a nonneu-
tralizing MAb directed against the HPV11 L1 protein (A3)
failed to do so (data not shown). Uptake of PV-reporter plas-
mid complexes was not affected by exposure to a preimmune
rabbit serum. These results suggest that binding and uptake of
the VLP-reporter plasmid complexes are mediated through a
specific interaction between the virus and a cellular recep-
tor(s).
FIG. 3. Analysis of b-Gal expression of HeLa cells after incubation with an
HPV6b VLP-reporter plasmid complex at 0.5 mg per well. (A) Cells exposed to
a mixture of unmodified VLPs and the reporter plasmid; (B) cells exposed to
VLP-reporter plasmid complexes; (C) cells infected with dl312 adenovirus and
exposed to a mixture of unmodified VLPs and reporter plasmid; (D) cells in-
fected with adenovirus dl312 (500 particles per cell) and exposed to VLP-re-
porter plasmid complexes.
FIG. 4. Hypothesis of the uptake mechanism of VLP-reporter plasmid com-
plexes by receptor-mediated endocytosis according to Cristiano et al. (6, 7).
Coincubation of the adenovirus and VLP-reporter plasmid complex results in the
binding and uptake of each component through its own receptor. The cointer-
nalization of these components into the same endosome results in the release of
the complex into the cytoplasm, allowing expression.
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Presence of the PV receptor on different cell lines. Since the
PV binding assays suggested that the putative PV receptor is
not restricted to epithelial cells, we examined 16 different cell
lines for their abilities to take up the VLP-reporter plasmid
complexes (Table 1). All cells demonstrated expression of the
b-Gal gene after lipofection of this plasmid. The cells were
then infected with adenovirus dl312, together with PV-reporter
plasmid complexes linked to HPV6b L1 VLPs. All cells but one
(FM cat skin cells) of those tested were shown to express the
lacZ gene (Table 1), suggesting that PV particles can be taken
up by a mechanism or receptor present in many tissues of a
variety of mammalian species.
Different PVs compete for the same entry pathway. To test if
different PVs use the same cellular uptake mechanism, we
examined unmodified HPV6b capsids for their abilities to in-
terfere with uptake of the reporter plasmid linked to VLPs
(HPV6b) and complete viral particles (BPV). An HPV6b L1
VLP-reporter plasmid complex (0.1 mg of protein per well) was
mixed with a suspension of PV capsids (HPV11, HPV16, or
BPV virions) at concentrations of 100 or 500 mg/ml, and the
mixtures were added to HeLa cell monolayers along with ad-
enovirus dl312. PV capsids competed with uptake of the
HPV6b VLP-reporter plasmid complex in dose-dependent
fashion, and VLPs of each genotype were inhibitory with sim-
ilar efficiency (Fig. 5B). When HPV11 or HPV16 capsids were
added 2 h after the HPV6b VLP-reporter plasmid complex, no
inhibition of b-Gal activity was observed. These results indi-
cated that different PV capsids use the same saturable pathway
to enter their host cells.
DISCUSSION
PVs are nonenveloped 50- to 60-nm icosahedral structures
(7) that are composed of highly conserved L1 major capsid and
less well-conserved L2 minor capsid proteins. The major capsid
protein has a molecular mass of approximately 55,000 Da (13,
14) and represents approximately 80% of the total viral pro-
tein. The minor capsid protein has a calculated molecular mass
of approximately 50,000 Da but migrates as about 70 to 80 kDa
in SDS-polyacrylamide gels (10, 19, 34). Recent high-resolu-
tion cryoelectron microscopic analysis of BPV1 and HPV1
virions has determined that the two viruses have very similar
structures, with 72 pentameric capsomeres, each of which is
presumably composed of five L1 molecules, forming a virion
shell with T 5 7 symmetry (1).
Virus-cell interaction, which represents the initial step in
virus infection, occurs on the plasma membranes of susceptive
cells and, in many instances, determines the virus host range (3,
23, 28, 29). PVs have a restricted tissue and host tropism;
however, the basis for this restriction is unknown. On the basis
of the following observations, it can be assumed that different
PV use related (or even identical) cellular receptor molecules
which do not seem to be restricted to a certain type of epithe-
lium. (i) The major structural protein L1 (which makes contact
with the cellular receptor, as shown in this report) is very well
conserved among different PVs (33). (ii) Although most of the
HPVs are restricted either to the skin (e.g., HPV1, -4, -60, -63,
and -65) or to the mucosa (e.g., HPV6, -11, -16, -18, -31, and
-45), there are certain HPV types, such as HPV2, -3, -7, -27,
and -57 that infect both the cutaneous and the mucosal epi-
thelia (8). (iii) BPV1 naturally infects bovine skin keratinocytes
and fibroblasts; however, under experimental conditions, it can
transform cells from different species in culture (20–22). (iv) A
recent study using radioactively labeled BPV1 particles iso-
lated from cattle warts as well as BPV and HPV16 VLPs
demonstrated binding to cells of 14 lines derived from different
tissues (epithelium, connective tissue, and neural crest) and
different species (humans, mice, and monkeys) (25, 26). It is,
therefore, reasonable to propose that the tropism of the PV
infection is (or is only partially) attributable not to specific
virus-cell interactions but to other steps of the PV life cycle,
such as regulation on the transcriptional level in host cells.
Details of the early events of PV infection, including the
nature and distribution of the PV receptor and the mecha-
nisms involved in the process of viral penetration, remain un-
clear, since no tissue culture system exists to support virus
propagation. To this end, many laboratories (including ours)
have developed the method of producing PV VLPs by expres-
sion of structural proteins in recombinant vectors (15, 17, 27,
37, 38). Here, we report that synthetic PV capsids consisting of
the PV L1 protein as well as complete infectious BPV virions
can be applied to the study of the initial interaction of PVs with
cells, i.e., attachment and penetration. In the binding assay, we
used an antigen capture ELISA to quantify the amount of L1
FIG. 5. (A) Inhibition of the uptake of PV-reporter plasmid complexes by
L1-specific antisera. Results for cells exposed to VLP-reporter plasmid com-
plexes preincubated with antisera are as indicated. Cells were stained for b-Gal
activity after 48 h, and the percentages of blue cells (of 1,000 cells counted) were
determined. The control (cells exposed to complexes treated with preimmune
serum) was set at 100%. (B) Inhibition of the uptake of different PV-reporter
plasmid complexes by unmodified HPV6b VLPs. Particle-reporter plasmid com-
plexes of HPV6b, HPV11, HPV16, and BPV were mixed with unmodified
HPV6b VLPs (0, 0.1, and 0.5 mg/ml), and the mixtures were added to HeLa cells
along with adenovirus dl312 at 500 particles per cell. The controls in both panels
A and B were set at 100%, and the mean values of reduction for different
antibody or particle concentrations are indicated. In both panels A and B, the
actual numbers of blue cells per 1,000 cells, which were counted in two inde-
pendent experiments, are indicated at the top of each column. The reduction of
the number of blue cells was calculated individually for both experiments. The
variations for the relative inhibition are shown by error bars.
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protein which failed to bind to cells in vitro, and we found that
a large range of cells (including SF9 insect cells) was able to
interact with PV capsids. Trypsinization of the cells prior to the
addition of the particles reduced binding ability, suggesting
that the cellular receptor might be of a protein nature.
Since this assay does not differentiate between particles at-
tached to the surface and those which have been taken into the
cells, we adapted a system which has been successful in the
delivery of many genes via different receptors (4, 6, 7, 35) to
study penetration of PV capsids into cells. We used complete
BPV particles as well as VLPs of HPV6b, HPV11, and HPV16,
which were all physically linked to DNA which codes for the
cytomegalovirus promoter-driven E. coli lacZ gene coding for
b-Gal, whose activity within the cells can be easily measured.
Penetration of VLP-reporter plasmid complexes seems to be
dependent on specific interactions between the PV capsids and
a cellular molecule(s) since unlinked PV capsids consistently
failed to deliver the reporter gene into the cell lines. Coinfec-
tion of cells with replication-defective adenovirus (dl312) en-
hanced the uptake of the VLP-reporter plasmid complexes by
more than 10- to 20-fold, very likely by the adenovirus-induced
lysis of lysosome membranes (24), indicating that the uptake of
PV capsids occurs through an endocytotic pathway (Fig. 4).
All but one (namely, FM cells derived from cat skin) of 16
different cell lines tested in this study that originate from dif-
ferent tissues and species (Table 1) turned out to be b-Gal
positive after coinfection by VLP-reporter plasmid complexes
and adenovirus dl312. The numbers of blue cells were similar
(about 10 to 20% of the cells) in all instances in the positive
cell lines. These data suggest that the VLP-reporter plasmid
complexes are delivered into the cells by receptor-mediated
endocytosis and that tissue difference and evolutionary diver-
gence have no effects on the abundance of the PV receptor
molecule(s). It has not yet been analyzed why the FM cells are
negative for uptake of the PV complexes. This deficiency might
be due to the absence of a functional PV-specific receptor.
However, the FM cells exhibited low affinity for HPV11 VLPs
in our binding assays and also showed a low level of DNA
transfection efficiency in a transfection assay. Further experi-
ments are required to characterize the ability of this cell line to
interact with PVs.
Specific antisera were shown to decrease capsid binding
and/or uptake, probably by blocking the binding to the PV
receptor, suggesting that the inhibition of the uptake of PV
capsids is virus type specific. However, even at a relatively high
concentration of antiserum, the blocking was not complete. It
is possible that during the attachment of poly-L-lysine to the
PV capsids, the particles disassembled into capsomeres, each
of which retained the ability to deliver DNA into the cells,
resulting in a deficiency of neutralizing antibodies. It also can-
not be ruled out that partial denaturation of the particles
changed the conformational epitopes but still retained the
ability of the particles to interact with the cellular receptor.
Incomplete blocking of binding of BPV1 has also been re-
ported by others, showing that a neutralizing BPV1 MAb only
partially blocked binding even at a high antibody-to-PV ratio
(26).
In our competition assay, a 5,000-fold excess of unlinked PV
capsids blocked only about two-thirds of PV-DNA capsids
from entering into HeLa cells. HPV6b, HPV16, and HPV11
capsids or BPV particles could block HPV6b capsid binding
and/or uptake with similar efficiencies. This result suggests that
all PVs share the same receptor molecule(s) to enter their host
cells. However, at the present time we are unable to distinguish
whether the competition of VLPs from different genotypes was
at the stage of binding or of uptake of the particles. Since we
failed to completely block the entry of HPV6b capsids into
cells, the PV receptor very likely is an abundant molecule that
is conserved in many different cells. The method described
here for uptake of PV capsids will be useful in determining the
neutralizing activities of MAbs raised against PV particles and
in detecting such antibodies in human sera or mucosal secre-
tions. Furthermore, this method can be applied to studying the
entry pathway of PVs into cells.
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